Basic Information
| LncRNA/CircRNA Name | KCNMA1-AS1 |
| Synonyms | NA |
| Region | GRCh38_10:76888044-76980624 |
| Ensemble | ENSG00000236467 |
| Refseq | NR_120655 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | epithelial ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot |
| Sample | Human normal ovarian cell line IOSE-386 and ovarian cancer cell lines HO8910, HEY and A2780, EOC, normal epithelial ovarian tissue |
| Expression Pattern | up-regulated |
| Function Description | KCNMA1-AS1 was a risk factor for prognosis in high-grade, advanced and serous EOC. Upregulated KCNMA1-AS1 was found in EOC tissues than that of normal tissues, showing the diagnostic potential of KCNMA1-AS1 in EOC. Statistical analysis indicated that KCNMA1-AS1 was not correlated with the DFS, OS, age, histological type, lymph node metastasis and recurrence, but related to FIGO stage of EOC patients. For in vitro experiments, the proliferation and migration of were enhanced, and apoptosis of HO8910 cells overexpressing KCNMA1-AS1 was inhibited. Furthermore, elevated expressions of Caspase-3 and Caspase-9, as well as reduced expression of Bcl-xL, were observed after KCNMA1-AS1 knockdown in EOC cells. |
| Pubmed ID | 31210304 |
| Year | 2019 |
| Title | KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer |
External Links
| Links for KCNMA1-AS1 | GenBank HGNC NONCODE |
| Links for epithelial ovarian cancer | OMIM COSMIC |